ADCC responses and blocking of EGFR-mediated signaling and cell growth by combining the anti-EGFR antibodies imgatuzumab and cetuximab in NSCLC cells
Arjan Kol; Anton Terwisscha van Scheltinga; Martin Pool; Christian Gerdes; Elisabeth G.E. de Vries; Steven de Jong · 2017 · Oncotarget
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
// Arjan Kol 1 , Anton Terwisscha van Scheltinga 2 , Martin Pool 1 , Christian Gerdes 3 , Elisabeth de Vries 1 , Steven de Jong 1 1 Department of Medical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 2 Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands 3 Roche Pharma Research & Early Development, Roche Innovation Center Zürich, Schlieren, Switzerland Correspondence to: Steven de Jong, email: s.de.jong@umcg.nl Keywords: non-small cell lung cancer,
Abstract by Arjan Kol; Anton Terwisscha van Scheltinga; Martin Pool; Christian Gerdes; Elisabeth G.E. de Vries; Steven de Jong, Oncotarget (2017) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
Negative / Null Result ReportDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
Negative / Null Result ReportStenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
Negative / Null Result ReportEffects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Replication FailureA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Negative / Null Result ReportSpironolactone for Heart Failure with Preserved Ejection Fraction
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.18632/oncotarget.17139